Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uterine Corpus Leiomyosarcoma: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Uterine Corpus Leiomyosarcoma: 3 US clinical trials tracked, none currently recruiting.
Uterine Corpus Leiomyosarcoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition uterine-corpus-leiomyosarcoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Uterine Corpus Leiomyosarcoma has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uterine Corpus Leiomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uterine Corpus Leiomyosarcoma is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
National Cancer Institute (NCI)
NCT03880019
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
NCT00025220
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Gynecologic Oncology Group
NCT00031629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Uterine Corpus Leiomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uterine Corpus Leiomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uterine Corpus Leiomyosarcoma page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Uterine Corpus Leiomyosarcoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Uterine Corpus Leiomyosarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Corpus Leiomyosarcoma condition card totals 3 registered trials; most-linked intervention Thalidomide; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.